These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26582647)

  • 1. Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.
    Zabriskie MS; Eide CA; Yan D; Vellore NA; Pomicter AD; Savage SL; Druker BJ; Deininger MW; O'Hare T
    Leukemia; 2016 Jun; 30(6):1418-21. PubMed ID: 26582647
    [No Abstract]   [Full Text] [Related]  

  • 2. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL1 compound mutations drive ponatinib resistance.
    Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib.
    Lasater EA; Massi ES; Stecula A; Politi J; Tan SK; Smith CC; Gunthorpe M; Holmes JP; Chehab F; Sali A; Shah NP
    Leukemia; 2016 Jun; 30(6):1405-9. PubMed ID: 26511402
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.
    Okabe S; Tauchi T; Tanaka Y; Sakuta J; Ohyashiki K
    J Hematol Oncol; 2015 Aug; 8():97. PubMed ID: 26239229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?
    Soverini S; Martelli M; Bavaro L
    Lancet Haematol; 2019 May; 6(5):e236-e237. PubMed ID: 31036315
    [No Abstract]   [Full Text] [Related]  

  • 7. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
    Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
    Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
    [No Abstract]   [Full Text] [Related]  

  • 8. Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia.
    Langabeer SE; McCarron SL; Haslam K; Preston L
    Clin Lab; 2016; 62(5):975-6. PubMed ID: 27349028
    [No Abstract]   [Full Text] [Related]  

  • 9. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
    Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
    Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
    Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.
    Giudice V; Ghelli Luserna di Rorà A; Serio B; Guariglia R; Giannini MB; Ferrari A; Simonetti G; Selleri C; Martinelli G
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
    Kamasani S; Akula S; Sivan SK; Manga V; Duyster J; Vudem DR; Kancha RK
    Tumour Biol; 2017 May; 39(5):1010428317701643. PubMed ID: 28475010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
    Shah NP
    Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chronic myelogenous leukemia: diagnosis and treatment].
    Demeter J; Poros A; Bödör C; Horváth L; Masszi T
    Orv Hetil; 2016 Sep; 157(37):1459-68. PubMed ID: 27615196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
    Baccarani M; Soverini S; De Benedittis C
    Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia.
    Langabeer SE; Haslam K; Crampe M; MacDonagh B; McHugh J
    Exp Oncol; 2019 Mar; 41(1):82-83. PubMed ID: 30932408
    [No Abstract]   [Full Text] [Related]  

  • 17. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
    Jabbour E; Morris V; Kantarjian H; Yin CC; Burton E; Cortes J
    Blood; 2012 Oct; 120(16):3382-3. PubMed ID: 23086624
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
    Cea M; Cagnetta A; Garuti A; Cirmena G; Rocco I; Moran E; Grillo V; Ballestrero A; Patrone F; Nencioni A
    J BUON; 2009; 14(4):565-73. PubMed ID: 20148444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
    Beel K; Janssens A; Verhoef G; Vandenberghe P
    Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.